Descrizione del progetto
Rendere gli isotopi medici più sicuri e più sostenibili in Europa
Il radio-223 è un isotopo radioattivo, un radionuclide usato per trattare il cancro metastatico. Ulteriori radionuclidi si dimostrano promettenti e potrebbero soddisfare la domanda futura; tuttavia, sono presenti diverse grandi sfide da affrontare prima di poterne usufruire. Per ovviare a questo problema, il progetto SECURE, finanziato dall’UE, individuerà e utilizzerà risorse esistenti per nuovi radionuclidi, in particolare per gli isotopi che emettono radiazioni alfa e beta. Pertanto, si propone di abbattere gli ostacoli decisivi alla produzione sostenibile e di fornire orientamenti e raccomandazioni per sfruttare appieno la terapia con particelle alfa e beta. Inoltre, il progetto metterà a disposizione le principali lezioni apprese per gestire i problemi di ampliamento e produzione sostenibile degli isotopi.
Obiettivo
SECURE project aims to make a major contribution to the sustainability of medical isotope production and its safe application in Europe. It is focusing on promising developments in the design of irradiation targets, production routes for existing and new isotopes in nuclear therapy and diagnostics. Isotopes critical in the success of nuclear medicine are selected and research activities are identified to address some of the major challenges in securing its future availability, with the objectives:
1. to remove critical barriers along the production of its selected alpha and beta emitting isotopes that restrict a sustainable production,
2. to develop a framework of guidance and recommendations that enables exploring the full clinical potential of alpha and beta particle therapy and its safe application
3. to provide important lessons learned that act as a demonstration case for addressing issues in upscaling and sustained isotope production.
At present, Ra-223 is the only radiopharmaceutical which has been granted marketing authorization to treat adults with prostate cancer. This has paved the way for a wider use of other alpha emitters such as Ac-225 or Bi-213. The expected demand of nuclear medicine for novel alpha emitters and beta- emitters requires re-evaluation of their production methods and inventories of target materials and parent radionuclides.
The ambition of SECURE consortium is to identify and efficiently use the current resources for new radionuclides, in particular for alpha emitters and the relevant beta emitting theranostic radionuclides. The development of alternative technologies for production of such therapeutic radionuclides for improved patient treatment requires multidisciplinary scientific and technological knowledge including physics, chemistry, material science, machining of target materials, chemistry, biology and radiobiology, radiopharmacy and nuclear medicine. All this chain of expertise is present in SECURE consortium.
Campo scientifico
CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP.
CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP.
Parole chiave
Programma(i)
Meccanismo di finanziamento
EURATOM-RIA - EURATOM Research and Innovation ActionsCoordinatore
05 400 Otwock
Polonia